Merck sees approval earlier than expected for Erbitux in Japan |
|
|
|
Published
:
Thu, 01 Mar 2007 16:07
|
DARMSTADT, Germany (AFX) - Merck KGaA said it expects to receive approval earlier than expected for use of its cancer drug Erbitux in Japan.Merck's chief financial officer Michael Becker said in an analyst telephone conference that the company is in the process of building up an infrastructure in Japan.In February, the company's Merck Serono division said an application had been submitted by Merck Ltd Japan and ImClone Systems Inc to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Erbitux in treating patients with advanced colorectal cancer.krysia.diver@afxnews.comkd/cmlCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
ImClone applies for Japan Erbitux OK 